PDF DatasheetHuman Anti-CD1a / HTA1 Antibody Product Attributes
CD1a / HTA1 Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in CD1a / HTA1 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in Langerhans in skin. More moderate antibody staining intensity was present in Langerhans in skin. Low, but measureable presence of CD1a / HTA1 could be seen infibroblasts in skin. We were unable to detect CD1a / HTA1 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of CD1a / HTA1 expression as measured by anti-CD1a / HTA1 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | + | – | – | – | + | + | – | + |
| CD1A Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | ++ | + | ++ | + | + | ++ |
| CD1a / HTA1 General Information | |
|---|---|
| Alternate Names | |
| CD1a, Cluster of Differentiation 1a, | |
| Molecular Weight | |
| 49kDa | |
| Chromosomal Location | |
| 1q23.1 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CD1A |
| Entrez Gene ID | 909 |
| Ensemble Gene ID | ENSG00000158477 |
| RefSeq Protein Accession(s) | NP_001307581, NP_001754 |
| RefSeq mRNA Accession(s) | NM_001320652, NM_001763 |
| RefSeq Genomic Accession(s) | NC_018912, NC_000001 |
| UniProt ID(s) | P06126 |
| UniGene ID(s) | P06126 |
| HGNC ID(s) | 1634 |
| Cosmic ID(s) | CD1A |
| KEGG Gene ID(s) | hsa:909 |
| PharmGKB ID(s) | PA26193 |
| General Description of CD1a / HTA1. | |
| At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. Anti-CD1a labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibodies against TTF-1 and CD5, anti-CD1a is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. Anti-CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa). | |
There are no reviews yet.